Press Release For Immediate Release

Glenmark Generics/LVT jointly announce the approval of two New Drug Applications(NDAs) by the USFDA

- **The approvals are for a line of controlled substance products containing Oxycodone Hydrochloride**

December 6, 2010 – Glenmark Generics Inc., U.S.A. (Glenmark), the United States subsidiary of Glenmark Generics Ltd, and Lehigh Valley Technologies (LVT) jointly announce the approval by the Food and Drug Administration of two New Drug Applications (NDAs) for a line of controlled substance products containing Oxycodone Hydrochloride (Oxycodone), along with their signing of a new Supply and Marketing Agreement between Glenmark and LVT.

The approved Oxycodone product line includes a 5 mg capsule and 100mg/5mL oral solution. The two approved NDAs provide Glenmark and LVT with manufacturing and distribution rights to the only FDA-approved Oxycodone immediate release capsules and oral solution currently available in the United States.

Under the terms of the exclusive Supply and Marketing Agreement between LVT and Glenmark, LVT will be responsible for the manufacture of the Oxycodone product line for Glenmark's exclusive marketing and distribution in generic form. LVT will retain exclusive marketing rights to the branded version of the Oxycodone product line. LVT will also retain exclusive marketing rights to additional strengths of the Oxycodone product line in both generic and branded forms, including but not limited to Oxycodone Hydrochloride HCl 5mg/5Ml oral solution.

According to IMS Health for the 12 month period ending September 2010, Oxycodone Hydrochloride immediate release oral solid capsule and liquid formulations represent total market sales of USD 13 million.

About Glenmark Generics Limited.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

About Lehigh Valley Technologies, Inc.
Lehigh Valley Technologies, Inc. (LVT) is a specialty pharmaceutical company located in Allentown, Pennsylvania. LVT is engaged in research, development and manufacture of controlled substances and innovative abuse deterrent technology and related product candidates.

#####

For further information, please contact:

Jason D'Souza

Glenmark, Mumbai, India Tel: [+91 22] 40189919

Email : connect@glenmark-generics.com